Posted inBiotechnology
BEGONIA trial: durvalumab plus trastuzumab deruxtecan for HER2-low metastatic breast cancer
In one of oncology’s most closely watched experiments, an antibody-drug conjugate paired with an immune checkpoint inhibitor has produced unusually…








